Moderna stock, traded under the ticker $MRNA, surged over 110% after the company announced the first ever positive Phase 3 results for a personalized cancer vaccine. Phase 3 is late-stage clinical testing conducted to assess a treatment’s effectiveness and safety before potential regulatory review.